Comparison of digital and analog [68Ga]Ga-PSMA-11 PET/CT for detecting post-prostatectomy biochemical recurrence in prostate cancer patients: a prospective study
-
Published:2024-07-01
Issue:1
Volume:14
Page:
-
ISSN:2045-2322
-
Container-title:Scientific Reports
-
language:en
-
Short-container-title:Sci Rep
Author:
Kim Yong-il,Lee Dong Yun,Sung Changhwan,Lee Sang Ju,Oh Seung Jun,Oh Jungsu S.,Yoon Shinkyo,Lee Jae Lyun,Lim Bumjin,Suh Jungyo,Park Juhyun,You Dalsan,Jeong In Gab,Hong Jun Hyuk,Ahn Hanjong,Kim Choung-Soo,Ryu Jin-Sook
Abstract
AbstractDigital positron emission tomography/computed tomography (PET/CT) has shown enhanced sensitivity and spatial resolution compared with analog PET/CT. The present study compared the diagnostic performance of digital and analog PET/CT with [68Ga]Ga-PSMA-11 in prostate cancer patients who experienced biochemical recurrence (BCR) after prostatectomy. Forty prostate cancer patients who experienced BCR, defined as serum prostate-specific antigen (PSA) concentrations exceeding 0.2 ng/mL after prostatectomy, were prospectively recruited. These patients were stratified into three groups based on their serum PSA levels. [68Ga]Ga-PSMA-11 was injected into each patient, and images were acquired using both analog and digital PET/CT scanners. Analog and digital PET/CT showed comparable lesion detection rate (71.8% vs. 74.4%), sensitivity (85.0% vs. 90.0%), and positive predictive value (PPV, 100.0% vs. 100.0%). However, digital PET/CT detected more lesions (139 vs. 111) and had higher maximum standardized uptake values (SUVmax, 14.3 vs. 10.3) and higher kappa index (0.657 vs. 0.502) than analog PET/CT, regardless of serum PSA levels. On both analog and digital PET/CT, lesion detection rates and interrater agreement increased with increasing serum PSA levels. Compared with analog PET/CT, digital PET/CT detected more lesions with a higher SUVmax and better interrater agreement in prostate cancer patients who experienced BCR after prostatectomy.
Funder
Ministry of Health and Welfare
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023). 2. Brawley, S., Mohan, R. & Nein, C. D. Localized prostate cancer: Treatment options. Am. Fam. Physician. 97, 798–805 (2018). 3. Paller, C. J. & Antonarakis, E. S. Management of biochemically recurrent prostate cancer after local therapy: Evolving standards of care and new directions. Clin. Adv. Hematol. Oncol. 11, 14–23 (2013). 4. Zhang-Yin, J., Montravers, F., Montagne, S., Hennequin, C. & Renard-Penna, R. Diagnosis of early biochemical recurrence after radical prostatectomy or radiation therapy in patients with prostate cancer: State of the art. Diagn. Interv. Imaging. 103, 191–199 (2022). 5. Maurer, T., Eiber, M., Schwaiger, M. & Gschwend, J. E. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 13, 226–235 (2016).
|
|